Facephi technology for HancomWith secures Good Software (GS), top-level certification for public sector deployment in South Korea

Notified -

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis